Osteologix, Inc. (OTC BB: OLGX), a specialty biopharmaceutical company, has dedicated their efforts to improving the health of those afflicted with musculoskeletal diseases through the development of innovative therapies. NB S101, the company’s lead investigational product candidate, is an innovative pharmaceutical agent designed to treat and prevent osteoporosis. Their mission is to partner with the healthcare community to apply new scientific information to the development of beneficial products. For more information please visit www.osteologix.com.
- 17 years ago
QualityStocks
Osteologix, Inc. (OTC BB: OLGX)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…